Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

This program funds early-stage product definition work for small molecules, biologics, and combination products for NHLBI mission-related diseases and disorders. It supports an R61 phase to identify, validate, and screen compounds and an R33 phase to identify lead series and do preliminary preclinical testing and optimization. Eligible applicants include U.S. higher education institutions, nonprofits, for-profit organizations, governments, tribal entities, and other U.S.-based organizations, but foreign organizations are not eligible to apply. Awards are limited to up to $400,000 in direct costs per year in each phase, with a maximum 3-year combined project period, and the R33 phase requires a non-federal cash match of at least 0.25:1. Clinical trials are not allowed, and the notice expects at least one Accelerator Partner for the R33 phase.

✳ AI-generated summary — verify against the announcement

• Health
• Research & Discovery
• Technology & Product Development
• Researchers & Scholars
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments